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Neuro-inflammation is a critical process by which the brain coordinates
chemokine-regulated cellular recruitment, cytokine release, and cell-mediated removal
of pathogenic material to protect against infection or brain injury. Dysregulation of this
immune response is involved in multiple neurodegenerative disorders, however the
precise contribution of neuro-inflammation to the exacerbation and progression of these
diseases remains unclear. Evidence now suggests that commensal micro-organisms
populating the host and their metabolites, collectively termed the microbiome,
regulate innate immunity by influencing peripheral immune cell populations, and
modulating microglial phenotype. Recent preclinical studies now demonstrate that
perturbations in the host microbiome can induce alterations in pathological phenotypes
associated with numerous neurodegenerative diseases. How perturbations in the host
microbiome and subsequently altered peripheral immune status are communicated to
the brain to influence neuro-inflammatory processes in these neurodegenerative
disease settings is far from understood. This review provides insight into the
regulation of neuro-inflammatory processes by the host microbiome in the context
of neurodegenerative disease and highlights the potential importance of the blood-brain
barrier and blood-cerebrospinal fluid-brain barrier, functioning as “immune barriers,”
to communicate host immune status to the brain. Understanding the mechanisms
by which the commensal microbiome communicates with the brain to influence
neuro-inflammatory processes will be critical in the development of microbially-targeted
therapeutics in the potential treatment of neurodegenerative disorders.
Keywords: microbiome, immunity, blood brain barrier, blood cerebrospinal fluid-brain barrier, Alzheimer’s disease,
Parkinson’s disease, stroke, neuro-inflammation
INTRODUCTION
Decades of research investigating neuro-inflammatory processes has supported the involvement
of resident surveying CNS cells (microglia/astrocytes), in initiating innate immune responses
that contribute to neurodegenerative disease pathology. Coordinated glial reactivity is required
for efficient removal of pathogenic insults and cellular debris arising from tissue injury, as
dysregulation of this CNS neuro-inflammatory response contributes to the progression of
neurodegenerative disorders including traumatic brain injury (TBI) (Karve et al., 2016), stroke
(Xiong et al., 2016), multiple sclerosis (MS) (Patejdl et al., 2016), Parkinson’s disease (PD) (Taylor
et al., 2013), and Alzheimer’s disease (AD) (Minter et al., 2016b). Within these neurodegenerative
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states, microglia exhibit a biased pro-inflammatory activation
state and great effort has beenmade to identify therapeutic means
by which to correct this bias, promoting anti-inflammatory and
neuroprotective microglial activities (reviewed in, Du et al.,
2016). Recent evidence now suggests that complex bilateral
communication between the peripheral immune status and
central immunity plays a key role in influencing various neuro-
inflammatory processes, including microglial activation.
A critical immunological compartment regulating general
host immune homeostasis (reviewed in, Honda and Littman,
2016) and microglial development is the microbiome, the
diverse commensal microbial community (and their metabolites)
that populate host tissues. C57BL/6 mice treated with broad-
spectrum combinatorial antibiotics (ABX), to depletemicrobiota,
or generated in gnotobiotic facilities (Germ-Free, GF) display
elevated microglial number, marked hypertrophy and alterations
in the transcriptome that governs basal microglial surveillance
(Erny et al., 2015). Upon exposure to lipopolysaccharide (LPS)
or lymphocytic choriomeningitis virus these microglia secreted
less pro-inflammatory cytokines and chemokines, suggesting that
GF microglia are either naïve to inflammatory stimuli or contain
adaptations that shift their activity toward an anti-inflammatory
state. Interestingly, supplementation with microbially-derived
short-chain fatty acids (SCFAs) was sufficient to restore the
microglial function of GF mice akin to specific-pathogen free
(SPF)-housed mice. Using a transcriptomics approach, microglia
isolated from GF mice displayed significantly down-regulated
expression of gene clusters associated with microglial maturation
and innate immune responses, specifically type-1 interferon
(IFN) signaling (Matcovitch-Natan et al., 2016). These studies
demonstrate an important role of commensal host microbiota
in regulating microglial development and homeostasis, hence
investigators are now interested in ascertaining the role of the
microbiome in brain health and neurodegenerative disease.
THE COMMENSAL MICROBIOME IN
NEURODEGENERATIVE DISEASES
The importance of exposure to diverse microbiota, from birth,
in promoting healthy neuronal development, and connectivity
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has long been documented (Kim et al., 2003; Juarez et al.,
2008). A recent study now demonstrates that ABX-induced
microbial perturbations results in basal and exercise-induced
hippocampal neurogenic defects (Mohle et al., 2016). This
deficit is attributed to the reduction in infiltrating Ly6Chi
monocytes, as adoptive transfer of these cells into ABX-treated
mice is sufficient to restore neurogenesis. ABX-inducedmicrobial
dysbioisis also worsens recovery after spinal cord injury in
mice, resulting in decreased white matter volume and enhanced
pro-inflammatory macrophage, CD45R+ B-cell and CD3+ T-
cell infiltration within the lesion epicenter (Kigerl et al., 2016).
Interestingly, probiotic supplementation post-spinal cord injury
enhances anti-inflammatory FoxP3+ T regulatory cell (T-reg)
recruitment and protects against white matter deterioration.
The host commensal microbiome also regulates neuronal
myelination whereby GF mice exhibit hyper-myelinated axons
in the pre-frontal cortex and enhanced expression of myelinating
gene clusters at the transcriptomics level (Hoban et al., 2016).
MS is a complex autoimmune disorder resulting in progressive
demyelination of CNS-residing neurons with sufferers possessing
altered gut microbial composition (Chen et al., 2016; Jangi
et al., 2016). Strikingly, Proteobacteria is readily detected
within inflammatory demyelinating lesions of cerebral white
matter (Branton et al., 2016). Prophylactic administration of
polysaccharide A (PSA), produced by the commensal Bacteroides
fragilis, alleviates experimental autoimmune encephalitis-
induced clinical-like symptoms, protects against demyelination
and reduces pro-inflammatory cytokine burden (Wang et al.,
2014). These beneficial observations result from PSA-induced
expansion of CD39+/CD4+ T-cell populations through toll-like
receptor (TLR)-2 signaling that regulate FoxP3+ T-reg function
within the cervical and mesenteric lymph nodes. These studies
suggest the microbiota influence critical immune compartments
and regulate neuronal development, myelination, and recovery
after injury. Given this, the field is now focusing on the role
of the microbiome in neurodegenerative diseases that exhibit
hallmark neuro-inflammatory pathology.
Stroke patients develop a vessel occlusion that deprives
downstream tissue of vital nutrients, triggering a primary area
of cell death. Upon tissue reperfusion a neuro-inflammatory
response is initiated that contributes to a secondary injury
termed the penumbra. ABX-treated mice subjected to the middle
cerebral artery occlusion (MCAO) model of ischemic stroke
display a 60% reduction in brain infarct volume and improved
sensorimotor function (Benakis et al., 2016). These mice display
elevated levels of FoxP3+ T-reg cells that suppress IL-17+
γδ T-cell proliferation and trafficking to the meninges post-
MCAO. The observed reduction in brain CXCL1 and CXCL2
expression then alleviates inflammatory leukocyte infiltration
within the infarct and improves outcome after the ischemic
event.
In AD, deposition of amyloid-beta (Aβ) confers a plaque-
localized neuro-inflammatory response that contributes to
disease progression. A recent study has now correlated specific
up-regulated pro-inflammatory gut bacteria with elevated pro-
inflammatory mediator expression in clinically diagnosed AD
patients (Cattaneo et al., 2016). Interestingly, AD sufferers
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exhibit increased susceptibility to bacterial infection and patients
display plaque deposition co-localized with E. coli-derived
LPS or K99 pili proteins (Zhan et al., 2016). Furthermore,
intra-cerebral injection of viable Salmonella Typhimurium
triggers seeding and accelerated Aβ deposition in 5xFAD
mice (Kumar et al., 2016). These findings were validated
in transgenic nematodes and reinforce the known anti-
microbial nature of Aβ (Soscia et al., 2010), but potentially
highlight a novel mechanism for AD exacerbation. A recent
study now provides evidence that GF Thy1-APPSWE/PS1L166P
mice exhibit reductions in Aβ pathology and microglial
reactivity (Harach et al., 2017). Additionally, ABX-induced
perturbations in the microbiome of APPSWE/PS11E9 mice alters
peripherally circulating cytokine profiles, confers reductions in
Aβ deposition and reduces plaque-localized gliosis (Minter et al.,
2016c). Both the aforementioned MCAO and APPSWE/PS11E9
mouse studies demonstrate that microbial abundance post-ABX
treatment recovers rapidly, however community diversity is
significantly reduced with both displaying dominant expansion
of Lachnospiraceae and Verrucomicrobiaceae. This implies
that it is not necessarily the sheer number of microbiota,
but rather their population diversity, that impact on host
physiology.
Similar to AD, alpha-synuclein (α-syn) deposition
observed in PD patients triggers a deposit-localized neuro-
inflammatory response that facilitates disease progression. One
un-conventional PD exacerbation hypothesis suggests that
aberrant gut-localized accumulation of α-syn propagates to
the brain via vagal nerve retrograde transport and stimulates
pathogenic α-syn seeding (Burke et al., 2008; Del Tredici and
Braak, 2008). Whilst this proposal remains controversial, it is
now documented that PD patients harbor distinct alterations in
microbial diversity of the gastrointestinal (GI) tract (Scheperjans
et al., 2015; Unger et al., 2016). A recent seminal study now
demonstrates that GF α-syn overexpressing mice display
improved motor function and attenuated α-syn aggregation
within the caudate putamen and substantia nigra in comparison
to SPF-housed mice (Sampson et al., 2016). These mice display
altered microglial morphology and reduced pro-inflammatory
TNFα and IL-6 cytokine load and these observations are
corroborated in ABX-treated α-syn mice. Supplementation of
GF α-syn mice with microbially-derived SCFAs exacerbated
motor deficits and importantly, GF mice colonized with fecal
matter from PD patients resulted in enhanced motor dysfunction
compared to mice that received material from healthy
controls.
Similar to Aβ, α-syn possesses anti-microbial activity against
multiple bacterial, yeast, and fungal strains (Park et al.,
2016). In subsequent AD and PD studies it will be critical
to address whether the attenuated Aβ and α-syn deposition
observed in microbially-perturbed mouse models is a direct
result of less protein seeding, due to a reduction in microbial
stimulus, or an altered host immune response that triggers
active peptide clearance. Regardless, these studies highlight the
importance of the commensal microbiome in regulating host
immunity and pathology in multiple neurodegenerative disease
settings.
ADDRESSING MICROBIOME-HOST
INTERACTIONS: A ROLE FOR IMMUNE
BARRIERS?
The aforementioned preclinical studies suggest that altering
microbial composition elicits distinct changes in host immune
compartments, impacting pathology in neurodegenerative
disease models. This may be through direct modulation
of microglial development and function within the brain
parenchyma or through alteration of peripheral immune cell
populations that communicate with the brain. The underlying
question remains how a perturbation in the microbiome is
communicated to the brain to induce functional changes and
confer phenotypic alterations observed in these preclinical
studies?
TLR expression on epithelial cells of the GI tract permits the
host to constantly survey and react to the luminal microbiome
(Mu et al., 2015). This monitoring mechanism ensures gut health
by modulating host-immune responses to ensure microbial
homeostasis. The vagal nerve innervates both mucosal villi and
epithelial layers of the GI tract and can be activated in response
to inflammatory mediators, produced from TLR signaling, or
microbially-derived metabolites to initiate communication of
the peripheral immune state to brain (Forsythe et al., 2014).
Subsequent activation of the hypothalamic-pituitary-adrenal axis
and the anti-inflammatory cholinergic neuronal reflex in the CNS
results in significant alterations of innate immunity (Petra et al.,
2015, Figure 1B).
Vagal nerve activation in response to gut microbial dysbiosis is
considered a major contributor to exacerbation of depressive and
autism spectrum disorders. Mice populated with Lactobacillus
rhamnosus displayed differential expression patterns of GABA
receptors throughout the brain and attenuated depressive
symptoms (Bravo et al., 2011). These beneficial probiotic effects
were not observed in vagotomized mice and additional evidence
describing similar beneficial effects of B. fragilis supplementation
in a maternally-immune activated anxiety mouse model supports
these findings (Hsiao et al., 2013). Alongside vagal activity
an autonomic nervous mechanism conferring gut microbial
perturbations following brain injury is also evident (Houlden
et al., 2016).
Despite the importance of vagal nerve stimulation in gut-brain
axis communication, there remains alternate immune barriers
of the brain that are critical in sensing the microbially-regulated
circulating peripheral inflammatory milieu (Figure 1C).
Blood Brain Barrier (BBB)
The BBB consists of capillary endothelial cells (connected by tight
junctions), astrocytes, and pericytes that form the neurovascular
unit responsible for barrier integrity (Sweeney et al., 2016).
These barrier units separate the CNS and systemic circulation,
thus regulating the brain microenvironment independently
from the circulating inflammatory milieu. Critically, loss of
BBB integrity significantly contributes to the progression
of neurodegenerative disorders including TBI (Price et al.,
2016), AD (Ryu and Mclarnon, 2009), and PD (Kortekaas
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FIGURE 1 | The microbiomes influence on host CNS health and neurodegenerative disease. Multiple pathways facilitate the bi-directional communication
between the microbiome and the CNS, influencing brain function. (A) Alterations in gut microbial composition and metabolomics profiles can induce (B) direct
stimulation of the vagal nerve, resulting in activation of the hypothalamic-pituitary-adrenal and regulation of innate CNS immune responses. (C) In addition,
microbially-regulated GALT immune cell populations and the commensal microbiota themselves can alter the circulating peripheral inflammatory milieu (including
cytokine profiles), which in turn play a key role in (D) the modulation of BBB integrity (via tight junction degradation) and (E) T cell infiltration at the BCSFBB. Alterations
(Continued)
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FIGURE 1 | Continued
in the gut microbial diversity may also influence (F) deleterious neuro-inflammatory CNS responses, including modulations in microglial reactivity, and cytokine
production, (G) impacting the progression of neurodegenerative disease states. α-syn, Alpha-synuclein; Aβ, Amyloid-beta; BBB, Blood-brain barrier; BCSFBB,
Blood-cerebrospinal fluid-brain barrier; CD, Cluster of differentiation; CNS, Central nervous system; CSF, Cerebrospinal fluid; DAMP, Damage-associated molecular
pattern; GALT, Gut-associated lymphoid tissue; IFN, Interferon; PAMP, Pattern-associated molecular pattern; TCR, T-cell receptor; Th, T-helper cell; T-reg, T-regulatory
cell; ZO, Zonula occludens.
et al., 2005). The commensal microbiota regulate peripheral
immune cell compartments, implicated in these disorders, and
secrete immunologically-active metabolites that circulate to the
brain. Thus, the question remains of how the microbiome
potentially regulates BBB permeability and stability (Figure 1D)
and what implications this has for inflammatory responses in
neurodegenerative diseases?
Indeed, gram positive bacterial components elicit pro-
inflammatory cytokine responses which alter tight junction
protein expression and disrupt BBB integrity in vitro (Boveri
et al., 2006). Microbial perturbations induced by feeding rodents
a “Western diet,” high in saturated fat and sugar (Claesson
et al., 2012), triggers increased BBB permeability and cognitive
deficits (Davidson et al., 2013). This observation suggests the
microbiome may be a previously un-recognized regulator of
BBB integrity. Indeed, a seminal study by Braniste et al.
demonstrated elevated BBB permeability in fetal and adult GF
mice independent of sex (Braniste et al., 2014). This BBB
dysfunction was associated with reduced expression of the
tight junction proteins occludin and claudin-5. Furthermore,
colonization of GF mice with flora from SPF mice restored
BBB integrity identified by reduced extravasation of Evans
blue dye into brain parenchyma, alongside restored expression
of occludin and claudin-5. Interestingly, these results were
also replicated when GF mice were mono-colonized with
the bacterial strains Clostridium tyrobutyricum and Bacteroides
thetaiotaomicron, both of which produce the SCFAs butyrate,
acetate and propionate. Collectively, these data highlight the
importance of specific microbial populations, particularly SCFA-
producing strains, in regulating BBB physiology.
The therapeutic benefits of butyrate, provided either as pure
sodium butyrate or generated by SCFA-producing bacteria,
has been recognized in neuropsychiatric disorders (Bourassa
et al., 2016), yet the underlying mechanism(s) by which it
influences BBB function remains unclear. In vivo evidence
suggests that the protective effect of sodium butyrate relates
to its ability to stabilize BBB integrity, with sodium butyrate
treated GF mice displaying reduced Evans blue extravasation in
multiple brain regions and increased occludin levels (Braniste
et al., 2014). In a model of transient focal cerebral ischemia
sodium butyrate attenuated BBB permeability, suppressed NFκB-
mediated production of MMP9, and prevented tight junction
degradation (Wang et al., 2011). In a mouse model of TBI,
decreased expression of occludin and Zonula Occludens-1 (ZO-
1) was identified 24 h post-injury, a response that was ameliorated
with sodium butyrate treatment, resulting in restoration of
BBB integrity and beneficial neurological outcomes (Li et al.,
2016). Whether these changes in barrier permeability induced by
circulating SCFAs involve direct effects on the brain endothelium
or indirect signaling by the enteroendocrine cells of the gut
warrants further investigation.
Microbial metabolites can also influence immune responses
in the periphery, which in turn affect BBB integrity through
activation of TLRs. Lipoteichoic acid (LTA), a cell wall
component of gram-positive bacteria and TLR2 agonist,
activates peripheral immune responses and downstream
signaling cascades, resulting in BBB dysfunction and behavioral
abnormalities. In this manner, intra-peritoneal administration of
bacillus subtilis-derived LTA increases pro-inflammatory IL-1β,
IL-6, TNFα, and IFNγ cytokine expression in the circulation
(Mayerhofer et al., 2017). These LTA-induced immunological
alterations are accompanied by decreased claudin-5, occludin
and tight junction protein-1 expression in the amygdala,
highlighting the capacity of LTA to influence BBB composition
through peripheral-CNS communication.
In addition to the regulation of BBB integrity by the
microbiome, astonishing new findings now suggest that the
microbiome impacts transport mechanisms across an intact
barrier. In this manner, microbially-derived peptidoglycan
(PGN) crosses the BBB, activating various PGN-recognition
proteins (Pglrp1, Pglrp2, Pglrp3, Pglrp4), as well as TLR2 and
the NOD-like receptors in the developing brain (Arentsen et al.,
2017).Manipulation of themicrobiome throughGF and/or ABX-
treated mice reduces CNS expression of the aforementioned
recognition proteins, as well as the PGN transporter (PepT1).
Interestingly, genetic deletion of Pglrp2 changes synapse-related
gene expression and induces sex-dependent variations in social
behavior, similar to that observed in microbially-perturbed mice
(Arentsen et al., 2017). These findings challenge traditional
view that microbial products only translocate into the brain
in situations of compromised BBB integrity. This discovery of
independent transit across the BBB and subsequent CNS immune
signaling presents a novel axis for future investigation into the
mechanism underlying microbiota-brain communication.
Blood-Cerebrospinal Fluid-Brain Barrier
(BCSFBB)
Diversification of themicrobiota and their metabolites is a critical
regulator of peripheral immune cell proliferation and activity
(Dorrestein et al., 2014). In particular, the microbiome closely
regulates the innate lymphoid cell populations of the gastro-
intestinal tract (Gury-Benari et al., 2016) and these cells can, in
turn, modulate T-cell populations residing in the lamina propia
and mesenteric lymph nodes (Sonnenberg and Artis, 2015). T-
cells circulate around the body and enter the brain via the choroid
plexus (CP) (Engelhardt and Ransohoff, 2005), responsible for
producing cerebrospinal fluid (CSF), whereby they contribute
to neuro-inflammatory events and modulate microglial activity.
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Hence alterations in the commensal microbiome may be
communicated to the brain via an altered immune status at the
BCSFBB (Figure 1E).
The composition of immune cells populating the CP has
important ramifications for neuro-inflammatory responses and
brain health. The CP is populated with a subset of CD4+ memory
T-cells that display T-cell receptor profiles unique to CNS-
derived antigens. In aged mice these cells favor a Th2 response
with elevated IL-4 and decreased type-2 IFNγ production
that stimulates the CP epithelium to drive CCL11 production
known to be deleterious to brain function (Villeda et al., 2011).
Experimentally-induced proliferation of memory T cells restored
the IL-4:IFNγ imbalance at the CP in these mice and prevented
cognitive deficits (Baruch et al., 2013). Additional studies have
now identified a CP-localized type-1 IFN response that drives
deleterious aging. Importantly, aged mice supplemented with
a type-1 IFN neutralizing antibody displayed reduced CCL11
expression, attenuated hippocampal glial reactivity, elevated
BDNF production, and improved neurogenesis (Baruch et al.,
2014). A dysregulated type-1 IFN signature has been observed in
aging disorders, that appear to be regulated by the microbiome,
including AD (Taylor et al., 2014; Minter et al., 2016a) and PD
(Main et al., 2016) and it is now considered that a balance of type-
1 and type-2 IFN signaling at the CP is required to impart healthy
brain immunity and aging (Deczkowska et al., 2016).
Studies now suggest that intervening with “immune
checkpoints” to re-correct immune cell phenotypes promotes
clearance of pathogenic peptides (Aβ or α-syn) and cellular
debris in neuro-degenerative disorders. Transient deletion of
FoxP3+ T-regs triggers an IFNγ-mediated immune activation
of the CP and results in recruitment of peripheral macrophages
and repopulating T-regs, facilitating removal of Aβ plaques
and restoring cognitive function in 5xFAD mice (Baruch et al.,
2015). Similar beneficial IFNγ-dependent immune activity and
Aβ clearance has also been demonstrated by programmed cell
death protein-1 (PD-1) immune checkpoint blockade in the
same animal model (Baruch et al., 2016). It is evident that re-
programming, not dampening, of immune responses is critical
in the treatment of neurodegenerative disorders. Considering
perturbations in commensal microbial diversity alter peripheral
T-cell compartments it will be critical to assess how these cell
populations are affected at the CP immune barrier. Furthermore,
it remains plausible that alterations in microbial diversity may
trigger transient changes in T-cell phenotypes recruited to
the CP that mimic the protective or deleterious phenotypes
of CP-recruited cells observed in the aforementioned studies.
Additional studies focusing on the BCSFBB in microbially-
perturbed neurodegenerative disease models will provide much
needed insight into how the commensal microbiome regulates
brain immunity and identify novel therapeutic targets.
CONCLUSION
Evidence presented from numerous studies now indicates
the commensal microbiome exhibits fine control over host
immunity that may have implications in developmental and
neurodegenerative disorders. The precise mechanisms by which
a perturbation in the host microbiome triggers alterations
in peripheral immune compartments and neuro-inflammatory
responses remains far from understood. We propose that
investigations focusing on “immune barriers” of the brain,
namely the BBB and BCSFBB, will provide important insights
into how the microbiome communicates with the brain and
we encourage future studies targeting the microbiome in
neurodegenerative diseases to address these barriers (Figure 1).
These studies may identify novel microbially-derived therapies to
induce host immunological alterations and treat these disorders.
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